KR970069031A - 당 제피로부터 스테로이드의 방출이 조절되는 약제학적 정제 - Google Patents

당 제피로부터 스테로이드의 방출이 조절되는 약제학적 정제 Download PDF

Info

Publication number
KR970069031A
KR970069031A KR1019970001419A KR19970001419A KR970069031A KR 970069031 A KR970069031 A KR 970069031A KR 1019970001419 A KR1019970001419 A KR 1019970001419A KR 19970001419 A KR19970001419 A KR 19970001419A KR 970069031 A KR970069031 A KR 970069031A
Authority
KR
South Korea
Prior art keywords
steroid
hormonal
pharmaceutical
sugar
pharmaceutical tablet
Prior art date
Application number
KR1019970001419A
Other languages
English (en)
Other versions
KR100482913B1 (ko
Inventor
레지날드 조우집 바콤
Original Assignee
버그 에곤이
아메리칸 홈 프로덕츠 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24554700&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR970069031(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 버그 에곤이, 아메리칸 홈 프로덕츠 코포레이션 filed Critical 버그 에곤이
Publication of KR970069031A publication Critical patent/KR970069031A/ko
Application granted granted Critical
Publication of KR100482913B1 publication Critical patent/KR100482913B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 정제 코어, 및 한회 복용량의 호르몬성 스테로이드 및 스테로이드 방출 속도 조절량의 미정질 셀룰로스를 함유하는 당 제피를 포함하는 약제학적 압축 정제에 관한 것이다.

Description

당 제피로부터 스테로이드의 방출이 조절되는 약제학적 정제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 약리학적 활성제를 전혀 함유하지 않거나 통상적으로 호르몬성 스테로이드와 함께 투여되는 하나 이상의 비스테로이드성 약리학적 활성제를 임의로 함유하는 내부 압축 코어, 및 외부 당 제피를 포함하는 약제학적 정제에서, 당 제피에 호르몬성 스테로이드 및 호르몬성 스테로이드 방출 속도 조절량이 미정질 셀룰로스가 혼입되어 있음을 특징으로 하는 약제학적 정제.
  2. 비약제화된 압축 코어 및 당 제피를 포함하는 약제학적 정제에서, 당 제피에 호르몬성 스테로이드 및 호르몬성 스테로이드 방출 속도 조절량의 미정질 셀룰로스가 혼입되어 있음을 특징으로 하는 약제학적 정제.
  3. 제1항에 있어서, 제피제 조성물에 존재하는 당이 수크로스인 약제학적 정제.
  4. 제1항에 있어서, 당 제피에 존재하는 호르몬성 스테로이드가 메드록시프로게스테론 아세테이트, 레보노르게스트렐, 게스토덴, 메드로게스톤, 에스트라디올, 에스트리올, 에티닐에스트라디올, 메스트라놀, 에스트논, 디에네스트롤, 헥세스트롤, 디에틸스틸비스트롤, 프로게스테론, 데소게스트렐, 노르게스티메이트, 하이드록시 프로게스테론, 노르에틴드론, 노르에틴돈 아세테이트, 노르게스트렐, 메게스트롤 아세테이트 메틸테스로스테론, 에틸에스트렌온, 메탄디엔온, 옥산드롤온, 트리메게스톤 또는 디에노게스트인 약제학적 정제.
  5. 제1항에 있어서, 당 제피에 존재하는 호르몬성 스테로이드가 RU-486, 오나프리스톤, ZK-137316, ORG-31730 또는 HRP-2000인 약제학적 정제.
  6. 제1항에 있어서, 당 제피가 수크로스, 미정질 셀룰로스 약 0.1 내지 약 3중량%, 0 내지 약 5중량% 양의 폴리비닐피롤리돈 및 약 0.1 내지 약 20중량% 양의 호르몬성 스테로이드를 포함하는 약제학적 정제.
  7. 제1항에 있어서, 당 제피가 에스트로겐 스테로이드 및 프로게스토겐 스테로이드를 함유하는 약제학적 정제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970001419A 1996-04-24 1997-01-20 당제피로부터스테로이드의방출이조절되는약제학적정제 KR100482913B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/637,139 US5759577A (en) 1995-01-17 1996-04-24 Controlled release of steroids from sugar coatings
US08/637139 1996-04-24

Publications (2)

Publication Number Publication Date
KR970069031A true KR970069031A (ko) 1997-11-07
KR100482913B1 KR100482913B1 (ko) 2005-08-05

Family

ID=24554700

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970001419A KR100482913B1 (ko) 1996-04-24 1997-01-20 당제피로부터스테로이드의방출이조절되는약제학적정제

Country Status (36)

Country Link
US (1) US5759577A (ko)
EP (1) EP0803250B1 (ko)
JP (1) JP4112648B2 (ko)
KR (1) KR100482913B1 (ko)
CN (1) CN1149982C (ko)
AR (1) AR005659A1 (ko)
AT (1) ATE218326T1 (ko)
AU (1) AU722188B2 (ko)
BR (1) BR9701904A (ko)
CA (1) CA2194428A1 (ko)
CO (1) CO4780019A1 (ko)
CY (1) CY2302B1 (ko)
CZ (1) CZ289762B6 (ko)
DE (1) DE69621588T2 (ko)
DK (1) DK0803250T3 (ko)
EG (1) EG23911A (ko)
ES (1) ES2179165T3 (ko)
HK (1) HK1003870A1 (ko)
HU (1) HU226397B1 (ko)
ID (1) ID16611A (ko)
IL (1) IL119976A (ko)
IS (1) IS1886B (ko)
MY (1) MY115223A (ko)
NO (1) NO315354B1 (ko)
NZ (1) NZ299823A (ko)
PL (1) PL187255B1 (ko)
PT (1) PT803250E (ko)
RU (1) RU2181586C2 (ko)
SG (1) SG64407A1 (ko)
SI (1) SI0803250T1 (ko)
SK (1) SK282484B6 (ko)
TR (1) TR199700052A3 (ko)
TW (1) TW487583B (ko)
UA (1) UA59333C2 (ko)
UY (1) UY24527A1 (ko)
ZA (1) ZA9610424B (ko)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
ES2152671T3 (es) * 1996-05-01 2001-02-01 Us Gov Health & Human Serv Derivados de progesterona sustituidos en posicion 21 como nuevos agentes antiprogestacionales.
CN1236435A (zh) * 1996-11-07 1999-11-24 奥索·麦克尼尔药品公司 一种固体甾族药物制剂的溶解测试方法
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
FR2801218B1 (fr) * 1999-11-23 2001-12-28 Hoechst Marion Roussel Inc Compositions pharmaceutiques comprenant de la trimegestone, leurs procedes de preparation ainsi que le conditionnement primaire les renfermant
AT500063A1 (de) 1999-11-23 2005-10-15 Sandoz Ag Beschichtete tablettenkerne
US6399591B1 (en) * 2000-01-19 2002-06-04 Yung-Shin Pharmaceutical Ind. Co., Ltd. Chargeable pharmaceutical tablets
US7989436B2 (en) 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
US6660726B2 (en) 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
US7459445B2 (en) * 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US20010034340A1 (en) * 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy
IL155959A0 (en) 2000-11-28 2003-12-23 Fmc Corp Edible pga (propylene glycol alginate) coating composition
JP4969747B2 (ja) * 2001-01-19 2012-07-04 武田薬品工業株式会社 錠剤フィルムコーティング用組成物
EA200301022A1 (ru) * 2001-03-16 2004-02-26 Уайт Гормональная заместительная терапия
TW200306196A (en) * 2002-04-03 2003-11-16 Wyeth Corp Hormone replacement therapy
TW200306846A (en) * 2002-04-03 2003-12-01 Wyeth Corp Hormone replacement therapy
TW200306851A (en) * 2002-04-29 2003-12-01 Wyeth Corp Hormone replacement therapy
TW200400040A (en) * 2002-05-17 2004-01-01 Wyeth Corp Hormone replacement therapy
US20060111577A1 (en) * 2003-02-28 2006-05-25 Kim Hyun K Method for preparing 17 alpha-acetoxy-11beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
US6992075B2 (en) * 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
CA2521471A1 (en) * 2003-04-11 2004-10-28 Barr Laboratories, Inc. Methods of administering estrogens and progestins
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
ES2933479T3 (es) * 2003-09-29 2023-02-09 Novo Nordisk Healthcare Ag Estabilidad mejorada de formulaciones de progestágenos
US20050271724A1 (en) * 2004-06-07 2005-12-08 Wyeth Sugar coatings and methods therefor
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US20060127451A1 (en) * 2004-09-23 2006-06-15 Michael Augello Coating composition
WO2006084082A1 (en) * 2005-02-03 2006-08-10 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
TW200738283A (en) * 2005-06-29 2007-10-16 Wyeth Corp Formulations of conjugated estrogens and bazedoxifene
WO2007058645A1 (en) * 2005-11-15 2007-05-24 Wm. Wrigley Jr. Company Tablets comprising a core and a medicament-containing coating for buccal release
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA2648280C (en) * 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
JP2010509350A (ja) * 2006-11-07 2010-03-25 ワイス エルエルシー 糖コーティングおよびその方法
JP2010511062A (ja) * 2006-11-29 2010-04-08 ワイス エルエルシー エストロゲン／ｓｅｒｍおよびエストロゲン／プロゲスチン二層錠剤
US8512745B2 (en) * 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
FR2997628B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
KR102221846B1 (ko) * 2014-04-07 2021-02-26 영진약품 주식회사 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법
US20170196816A1 (en) * 2014-06-02 2017-07-13 Nipro Corporation Laser-printable tablet, and method for manufacturing the same
MX2017005163A (es) 2014-11-17 2018-01-18 Arno Therapeutics Inc Composiciones de liberación prolongada de onapristona y métodos.
BR112018005999A2 (pt) 2015-09-25 2019-01-08 Context Biopharma Inc métodos para a produção de intermediários de onapristona
CN108883067B (zh) 2015-12-15 2021-03-09 康特斯生物制药公司 非晶奥那司酮组合物及其制备方法
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
US4191741A (en) * 1978-09-22 1980-03-04 Eli Lilly And Company Removable drug implant
US4248856A (en) * 1979-07-10 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4425339A (en) * 1981-04-09 1984-01-10 Syntex (U.S.A.) Inc. Treatment of menopausal symptoms
US4390531A (en) * 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
GB8403360D0 (en) * 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
US4755386A (en) * 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
US4927816A (en) * 1987-08-20 1990-05-22 Ester George C Formulae and methods for sublingual ingestion of natural progesterone
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
JP2542122B2 (ja) * 1990-04-18 1996-10-09 旭化成工業株式会社 球状核、球形顆粒およびその製造方法
US5223268A (en) * 1991-05-16 1993-06-29 Sterling Drug, Inc. Low solubility drug-coated bead compositions
WO1994009762A1 (en) * 1992-11-05 1994-05-11 Merck & Co., Inc. Drug delivery device
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings

Also Published As

Publication number Publication date
CN1163103A (zh) 1997-10-29
ATE218326T1 (de) 2002-06-15
KR100482913B1 (ko) 2005-08-05
CN1149982C (zh) 2004-05-19
HK1003870A1 (en) 1998-11-13
RU2181586C2 (ru) 2002-04-27
MX9700515A (es) 1997-10-31
PT803250E (pt) 2002-09-30
AU7181996A (en) 1997-10-30
IL119976A0 (en) 1997-04-15
NZ299823A (en) 1998-09-24
EG23911A (en) 2007-12-30
UA59333C2 (uk) 2003-09-15
DE69621588D1 (de) 2002-07-11
SG64407A1 (en) 1999-04-27
CZ6897A3 (en) 1997-11-12
HUP9603151A3 (en) 1998-11-30
NO970094L (no) 1997-10-27
ES2179165T3 (es) 2003-01-16
SK5597A3 (en) 1997-11-05
US5759577A (en) 1998-06-02
NO970094D0 (no) 1997-01-09
TW487583B (en) 2002-05-21
PL187255B1 (pl) 2004-06-30
EP0803250A1 (en) 1997-10-29
DK0803250T3 (da) 2002-09-09
JPH09291027A (ja) 1997-11-11
IL119976A (en) 2000-10-31
AR005659A1 (es) 1999-07-14
SI0803250T1 (en) 2002-10-31
EP0803250B1 (en) 2002-06-05
HU9603151D0 (en) 1997-01-28
NO315354B1 (no) 2003-08-25
JP4112648B2 (ja) 2008-07-02
PL317923A1 (en) 1997-10-27
CZ289762B6 (cs) 2002-04-17
CO4780019A1 (es) 1999-05-26
BR9701904A (pt) 1998-11-10
AU722188B2 (en) 2000-07-27
HU226397B1 (en) 2008-11-28
CY2302B1 (en) 2003-07-04
TR199700052A2 (xx) 1997-11-21
HUP9603151A2 (en) 1997-12-29
CA2194428A1 (en) 1997-10-25
ZA9610424B (en) 1998-06-11
ID16611A (id) 1997-10-23
TR199700052A3 (tr) 1997-11-21
MY115223A (en) 2003-04-30
DE69621588T2 (de) 2003-01-30
UY24527A1 (es) 2000-09-29
IS4385A (is) 1997-10-25
IS1886B (is) 2003-09-01
SK282484B6 (sk) 2002-02-05

Similar Documents

Publication Publication Date Title
KR970069031A (ko) 당 제피로부터 스테로이드의 방출이 조절되는 약제학적 정제
KR960028919A (ko) 당 피막으로부터 스테로이드의 조절된 방출
RU97100300A (ru) Контролируемое освобождение стероидов из сахарных покрытий
Kuhl Comparative pharmacology of newer progestogens
US5633242A (en) Pharmaceuticals for contraception/hormone substitution containing a biogenous estrogen component
Sitruk-Ware Pharmacology of different progestogens: the special case of drospirenone
Sitruk-Ware et al. Nestorone®: clinical applications for contraception and HRT
Muhn et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity.
Sitruk-Ware et al. The use of newer progestins for contraception
Sitruk-Ware New progestogens: a review of their effects in perimenopausal and postmenopausal women
Stanczyk All progestins are not created equal
Sitruk-Ware Progestogens in hormonal replacement therapy: new molecules, risks, and benefits
Foster et al. Dienogest
Stanczyk et al. Radioimmunoassay of serum d-norgestrel in women following oral and intravaginal administration
RU96100843A (ru) Композиция на основе сахара для нанесения на таблетку, прессованная таблетка
Schindler The “newer” progestogens and postmenopausal hormone therapy (HRT)
US6043234A (en) Method for treating endometriosis or leiomyomata uteri with a competitive progesterone antagonist and a gestagen
AU716249B2 (en) Contraceptive process and kit for female mammals that consists of a combination of gestagen and estrogen
CA2179728A1 (en) Composition for a contraceptive comprising an estrogen and a gestagen
KR970701039A (ko) 성 스테로이드를 함유하는 경피 치료 시스템(Sexual Steroid-Containing Transdermal Therapeutic Systems)
RU98101254A (ru) Фармацевтический комбинированный препарат, комплект инструмента и метод гормональной контрацепции
JPH09510183A (ja) 複合避妊薬
SK3102003A3 (en) Contraception process and administration form for the same
NO179311B (no) Flerfasekombinasjons- og kontraseptiv pakke
Fruzzetti et al. Review of clinical experience with estradiol in combined oral contraceptives

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment
FPAY Annual fee payment
FPAY Annual fee payment

Payment date: 20160330

Year of fee payment: 12

EXPY Expiration of term